Taia T Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10583600/publications.pdf Version: 2024-02-01



TALA T MANC

#	Article	IF	CITATIONS
1	Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain. MBio, 2010, 1, .	4.1	460
2	Type I and type II Fc receptors regulate innate and adaptive immunity. Nature Immunology, 2014, 15, 707-716.	14.5	425
3	lgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science, 2017, 355, 395-398.	12.6	286
4	New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nature Communications, 2021, 12, 5417.	12.8	286
5	Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18979-18984.	7.1	273
6	Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins. PLoS Pathogens, 2010, 6, e1000796.	4.7	251
7	Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2573-2578.	7.1	244
8	Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature Immunology, 2021, 22, 67-73.	14.5	239
9	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell, 2015, 162, 160-169.	28.9	171
10	Signaling by Antibodies: Recent Progress. Annual Review of Immunology, 2017, 35, 285-311.	21.8	167
11	Functional diversification of IgGs through Fc glycosylation. Journal of Clinical Investigation, 2019, 129, 3492-3498.	8.2	115
12	Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis. Science, 2012, 335, 1463-1463.	12.6	108
13	Why Do Influenza Virus Subtypes Die Out? A Hypothesis. MBio, 2011, 2, .	4.1	103
14	Unraveling the Mystery of Swine Influenza Virus. Cell, 2009, 137, 983-985.	28.9	97
15	The Role and Function of Fcl 3 Receptors on Myeloid Cells. Microbiology Spectrum, 2016, 4, .	3.0	96
16	Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Science Translational Medicine, 2022, 14, eabn7842.	12.4	92
17	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	13.7	75
18	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	12.4	71

TAIA T WANG

#	Article	IF	CITATIONS
19	H5N1 influenza viruses: Facts, not fear. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2211-2213.	7.1	61
20	FcRn, but not Fcl̂ ³ Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12943-12951.	7.1	55
21	Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Reports, 2020, 31, 107642.	6.4	44
22	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10172-10177.	7.1	42
23	lgC Fc Glycosylation in Human Immunity. Current Topics in Microbiology and Immunology, 2019, 423, 63-75.	1.1	38
24	The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses. Vaccines, 2018, 6, 36.	4.4	30
25	A Nine-Segment Influenza A Virus Carrying Subtype H1 and H3 Hemagglutinins. Journal of Virology, 2010, 84, 8062-8071.	3.4	29
26	Catching a Moving Target. Science, 2011, 333, 834-835.	12.6	24
27	Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Current Opinion in Immunology, 2018, 53, 124-129.	5.5	24
28	An aberrant inflammatory response in severe COVID-19. Cell Host and Microbe, 2021, 29, 1043-1047.	11.0	24
29	Immune Complexes: Not Just an Innocent Bystander in Chronic Viral Infection. Immunity, 2015, 42, 213-215.	14.3	20
30	Heterogeneity in IgG D16 signaling in infectious disease outcomes*. Immunological Reviews, 2022, 309, 64-74.	6.0	9
31	The Role and Function of Fc \hat{I}^3 Receptors on Myeloid Cells. , 2017, , 405-427.		8
32	Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19. Viruses, 2022, 14, 553.	3.3	7
33	Response to Comment on "Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis― Science, 2012, 336, 1506-1506.	12.6	4
34	Harnessing IgG Fc glycosylation for clinical benefit. Current Opinion in Immunology, 2022, 77, 102231.	5.5	3
35	Immunoglobulin E sialylation regulates allergic responses. Immunology and Cell Biology, 2020, 98, 617-619.	2.3	2
36	Illuminating the Fc dependence of SARS-CoV-2 neutralization. Immunity, 2021, 54, 1912-1914.	14.3	1